Acelrx pharmaceuticals reports first quarter 2022 financial results and provides corporate update

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million completed acquisition of lowell therapeutics and nafamostat franchise, including niyad™ with breakthrough device designation  continued dsuvia sales momentum with fourth consecutive quarter of sales volume growth, including 64% commercial (ex-dod) growth in q1 2022 compared to q4 2021 $39.3 million of cash and short-term investments at march 31, 2022 webcast and conference call to be held today at 8:30 am edt hayward, calif. , may 16, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2022 financial results.
ACRX Ratings Summary
ACRX Quant Ranking